

FORM PTO-1390
(REV 10-95)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

**TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. §371**

MERCK 2305

U.S. APPLICATION NO. (If known, see 37 CFR §1.5)

09/936660

INTERNATIONAL APPLICATION NO.

INTERNATIONAL FILING DATE

PCT/EP00/01974

7 MARCH 2000

PRIORITY DATE CLAIMED

17 MARCH 1999

TITLE OF INVENTION

**METHOD FOR PRODUCING COSMETIC OR PHARMACEUTICAL FORMULATIONS BY MEANS OF A
MICROMIXTURE DIRECTLY BEFORE USE**

APPLICANT(S) FOR DO/EO/US

ZUR LAGE, Jutta, et al.



Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. §371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. §371.
3. ☐ This express request to begin national examination procedures (35 U.S.C. §371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. §371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. §371(c)(2))
 - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☒ has been transmitted by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ A translation of the International Application into English (35 U.S.C. §371(c)(2)).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. §371(c)(3))
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. §371(c)(3)).
9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. §371(c)(4)).
10. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. §371(c)(5)).

Items 11. to 16. below concern document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 C.F.R. §§1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 C.F.R. §§3.28 and 3.31 is included.
13. ☒ A **FIRST** preliminary amendment.

☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☐ Other items or information:

U.S. APPLICATION NO. (if known, see 37 CFR §1.5) 09/936660		INTERNATIONAL APPLICATION NO. PCT/EP00/01974		ATTORNEY'S DOCKET NUMBER MERCK 2305	
17. <input checked="" type="checkbox"/> The following fees are submitted: BASIC NATIONAL FEE (37 CFR §1.492 (a) (1) - (5)): Search Report has been prepared by the EPO or JPO..... \$860.00 International preliminary examination fee paid to USPTO (37 CFR §1.482)..... \$690.00 No international preliminary examination fee paid to USPTO (37 CFR §1.482) but international search fee paid to USPTO (37 CFR §1.445(a)(2))..... \$710.00 Neither international preliminary examination fee (37 CFR §1.482) nor international search fee (37 CFR §1.445(a)(2)) paid to USPTO..... \$1000.00 International preliminary examination fee paid to USPTO (37 CFR §1.482) and all claims satisfied provisions of PCT Article 33(2)-(4)..... \$100.00 ENTER APPROPRIATE BASIC FEE AMOUNT =				CALCULATIONS PTO USE ONLY	
Surcharge of \$130.00 for furnishing the oath or declaration later than months from the earliest claimed priority date (37 C.F.R. §1.492(e)). <input type="checkbox"/> 20 <input type="checkbox"/> 30					
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	15 - 20 =	0	x \$ 18.00	\$0.00	
Independent claims	5 - 3 =	2	x \$ 80.00	\$160.00	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$ 270.00		
TOTAL OF ABOVE CALCULATIONS =				\$1,020.00	
Reduction of 1/2 for filing by small entity, if applicable. A Verified Small Entity Statement must also be filed (Note 37 C.F.R. §§1.9, 1.27, 1.28).					
SUBTOTAL =				\$1,020.00	
Processing fee of \$130.00 for furnishing the English translation later than months from the earliest claimed priority date (37 C.F.R. §1.492(f)). <input type="checkbox"/> 20 <input type="checkbox"/> 30					
TOTAL NATIONAL FEE =				\$1,020.00	
Fee for recording the enclosed assignment (37 C.F.R. §1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 C.F.R. §§3.28, 3.31). \$40.00 per property.					
TOTAL FEES ENCLOSED =				\$1,020.00	
				Amount to be refunded:	
				charged:	
a. <input checked="" type="checkbox"/> A check in the amount of <u>\$1,020.00</u> to cover the above fees is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. <u>13-3402</u> in the amount of \$_____ to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>13-3402</u> . A duplicate copy of this sheet is enclosed.					
NOTE: Where an appropriate time limit under 37 C.F.R. §§1.494 or 1.495 has not been met, a petition to revive (37 C.F.R. §1.137(a) or (b)) must be filed and granted to restore the application to pending status.					
SEND ALL CORRESPONDENCE TO: Customer Number 23,599					
 23599 PATENT TRADEMARK OFFICE			 SIGNATURE Harry B. Shubin NAME <u>32,004</u> REGISTRATION NUMBER		
Filed: 14 SEPTEMBER 2001					
HBS:kmo					

IN THE UNITED STATES DESIGNATED/ELECTED OFFICE

International Application No. : PCT/EP00/01974
International Filing Date : 7 MARCH 2000
Priority Date(s) Claimed : 17 MARCH 1999
Applicant(s) (DO/EO/US) : ZUR LAGE, Jutta, et al.
Title: METHOD FOR PRODUCING COSMETIC OR PHARMACEUTICAL
FORMULATIONS BY MEANS OF A MICROMIXTURE DIRECTLY BEFORE
USE

PRELIMINARY AMENDMENT

Commissioner for Patents
Washington, D.C. 20231

SIR:

Prior to calculating the national fee, and prior to examination in the National Phase of the above-identified International application, please amend as follows:

IN THE CLAIMS:

3. (Amended) Process according to Claim 1, characterized in that two or more components in liquid form, if necessary after warming, from separate stock chambers are passed through a temperature-controlled micromixer for mixing and subsequently stirred.
6. (Amended) Process according to Claims 1, characterized in that the components to be mixed are pumped from the stock chambers and fed into a micromixer through connecting thin tubes, each of which terminates in a channel of the micromixer, and forced through the channels of the micromixer owing to the pressure building up due to the pumping, with intensive mixing and formation of an emulsion.

7. (Amended) Process according to Claim 1, characterized in that the components to be mixed are pumped from the pressurized stock chambers, fed into a micromixer through connecting thin tubes, each of which terminates in a channel of the micromixer, and forced through the channels of the micromixer owing to the pressure which builds up due to the pumping, with intensive mixing and formation of an emulsion.

10. (Amended) Process according to Claim 8, characterized in that characterized in that the components to be mixed are pumped from the stock chambers and fed into a micromixer through connecting thin tubes, each of which terminates in a channel of the micromixer, and forced through the channels of the micromixer owing to the pressure which builds up due to the pumping, with intensive mixing and formation of a liposome-containing formulation.

11. (Amended) Process according to Claim 8, characterized in that the components to be mixed are pumped from pressurized stock chambers and fed into a micromixer through connecting thin tubes, each of which terminates in a channel of the micromixer, and forced through the channels of the micromixer owing to the pressure which builds up due to the pumping, with intensive mixing and formation of a liposome-containing formulation.

12. (Amended) Lotion or solution, prepared by a process according to Claim 1.

13. (Amended) Emulsion, prepared by a process according to Claim 1.

14. (Amended) Gel, prepared by a process according to Claim 1.

15. (Amended) Cream, prepared by a process according to Claim 1.

REMARKS

The purpose of this Preliminary Amendment is to eliminate multiple dependent claims in order to avoid the additional fee. Applicants reserve the right to reintroduce claims to canceled combined subject matter.

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached pages are captioned "**Version With Markings to Show Changes Made**".

Respectfully submitted,



Harry B. Shubin, Reg. No. 32,004
Attorney for Applicants
MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
Arlington Courthouse Plaza 1
2200 Clarendon Boulevard, Suite 1400
Arlington, VA 22201
Direct Dial: 703-812-5306
Facsimile: 703-243-6410
Email: shubin@mwzb.com

AJZ(HBS):jmm

Filed: 14 SEPTEMBER 2001

VERSION WITH MARKINGS TO SHOW CHANGES MADE

Claims 3, 6-7 and 10-15 have been amended as follows:

3. (Amended) Process according to Claims 1 ~~to~~ 2, characteriszed in that two or more components in liquid form, if necessary after warming, from separate stock chambers are passed through a temperature-controlled micromixer for mixing and subsequently stirred.

6. (Amended) Process according to Claims 1 ~~to~~ 5, characteriszed in that the components to be mixed are pumped from the stock chambers and fed into a micromixer through connecting thin tubes, each of which terminates in a channel of the micromixer, and forced through the channels of the micromixer owing to the pressure building up due to the pumping, with intensive mixing and formation of an emulsion.

7. (Amended) Process according to Claims 1, 4 ~~to~~ 6, characteriszed in that the components to be mixed are pumped from the pressuriszed stock chambers, fed into a micromixer through connecting thin tubes, each of which terminates in a channel of the micromixer, and forced through the channels of the micromixer owing to the pressure which builds up due to the pumping, with intensive mixing and formation of an emulsion.

10. (Amended) Process according to Claims 8 ~~to~~ 9, characteriszed in that characteriszed in that the components to be mixed are pumped from the stock chambers and fed into a micromixer through connecting thin tubes, each of which terminates in a channel of the micromixer, and forced through the channels of the micromixer owing to the pressure which builds up due to the pumping, with intensive mixing and formation of a liposome-containing formulation.

11. (Amended) Process according to Claims 8 ~~to~~ 10, characteriszed in that the

components to be mixed are pumped from pressurized stock chambers and fed into a micromixer through connecting thin tubes, each of which terminates in a channel of the micromixer, and forced through the channels of the micromixer owing to the pressure which builds up due to the pumping, with intensive mixing and formation of a liposome-containing formulation.

12. (Amended) Lotion or solution, prepared by a process according to Claims ~~1~~ to ~~11~~ 1.
13. (Amended) Emulsion, prepared by a process according to Claims ~~1~~ to ~~11~~ 1.
14. (Amended) Gel, prepared by a process according to Claims ~~1~~ to ~~11~~ 1.
15. (Amended) Cream, prepared by a process according to Claims ~~1~~ to ~~11~~ 1.

09/936660

10 Rec'd PCT
17 MAY 2001

Merck Patent Gesellschaft
mit beschränkter Haftung
64271 Darmstadt

Process for the preparation of cosmetic
formulations

09/936660-09270

In the preparation of emulsions, suspensions and dispersions which are delivered to the end consumer, it is desirable to obtain products which are stable for an extended period, do not tend to separate out and in which at the same time the added active ingredients retain their activity. The stability of mixtures is achieved in conventional products by the addition of additives, such as, for example, emulsifiers, surfactants or the like. In order to prevent decomposition of the contents and to hinder a decrease in the activity of active ingredients present, oxidation stabilisers, free-radical scavengers, bactericides and other additives, for example, are added. Various of these additives may result in irritation or allergies in the case of sensitive users.

In order to stabilise active ingredients, it is in many cases not the active ingredient itself that is used, but instead one of its more stable derivatives, which then decomposes at the site of action and liberates the active ingredient. This is of course afflicted with the problem that the derivative behaves differently to the actual active ingredient in any prior transport or metabolism processes which are necessary.

A further problem in the preparation of the above-mentioned mixtures is homogeneous mixing of the individual substances in each volume element of the mixture as a whole.

In order to prepare cosmetic formulations, simple stirred vessels with various types of stirrer are frequently used. Depending on the stirrer type (for example anchor, propeller, inclined-blade, disc, EKATO multistage impulse countercurrent stirrers or EKATO Mizer disc), different shear forces occur in the stirred vessels depending on the location in the stirred vessel. The same applies to the temperature distribution and energy input into the formulation, which means that shear forces, temperature and introduced energy are not "uniformly" distributed in the batch vessel, and consequently the build-up of the resultant formulation is adversely affected. In concrete terms, this means that, for example, emulsions may form in which the emulsified phase has very different particle sizes, or the active-ingredient distribution in a prepared product is non-uniform.

The object of the present invention is therefore to provide a process which gives mixed products which have a homogeneous distribution of all

components in the mixture as a whole and at the same time have a homogeneous distribution of the particle or droplet size. A further object of the invention is to provide a process for the preparation of cosmetic or pharmaceutical formulations by means of which the use of emulsifiers, surfactants, stabilisers, oxidation stabilisers, free-radical scavengers, bactericides and other additives can be restricted or by means of which, in the ideal case, their use can be omitted entirely. A further object of the invention is to provide a process by means of which cosmetic or pharmaceutical formulations can be prepared in very small amounts immediately before their use.

The object according to the invention is achieved by a process for the preparation of cosmetic or pharmaceutical formulations immediately before use, characterised in that two or more liquid components from separate stock chambers are mixed with one another by passing them through a micromixer.

In order to carry out the process according to the invention, two or more components in liquid form, if necessary after warming, from separate stock chambers are passed through a micromixer for mixing.

The mixing can take place by passing the components in liquid form, if necessary after warming, from separate stock chambers through a temperature-controlled micromixer and if necessary continuing stirring for cooling.

The process for the preparation of cosmetic or pharmaceutical formulations in the form of emulsions immediately before use can be carried out by passing one or more liquid component(s) with one or more natural, synthetic or semi-synthetic oil(s) from separate stock chambers through a micromixer, during which they are mixed with one another.

The object according to the invention is also achieved by a process for the preparation of cosmetic formulations in the form of emulsions immediately before use, characterised in that a fat phase consisting of one or more natural, synthetic or semi-synthetic oil(s) and one or more fat(s) which is

to the pressure prevailing in the stock chambers, an adequate pressure is built up in the micromixer to force the components through the channels with intensive mixing and formation of a liposome-containing formulation.

5 The present invention is also achieved by means of lotions or solution, emulsions, gels and creams which can be prepared by the process according to the invention.

10 For certain formulations, uniform mixing, a constant temperature and uniform input of energy even at the micro-level, are important. It has now been found that the use of micromixers enables the preparation of mixtures in the form of emulsions, suspensions and dispersions, lotions, solutions gels and creams in which all contents are uniformly distributed, even in extremely small volume parts. In contrast to a large-volume stirred reactor, it is possible to prepare these mixtures under uniform temperature conditions, even at the micro-level, since no temperature gradient forms in the thin, optionally laminate-like channels, in particular if the micromixer has a temperature-controllable design. Furthermore, the input of energy is the same in each volume part, i.e. even in the smallest. It has also been found that emulsions having a significantly more homogeneous droplet size distribution can be prepared than in a stirred vessel. Owing to the multiple shear conditions of the communicating channels in the micromixer, droplet sizes in the micro-range are inevitably specified, so that microemulsions are obtained, which could only be prepared in a very complex manner in a stirred vessel. The use of a micromixer is therefore suitable for the preparation of very fine homogeneous formulations.

30 Suitable for carrying out the process according to the invention are micromixers and associated connection and sealing systems which are described in the patent applications DE 1 95 11 603, DE 1 97 46 583, DE 1 97 46 584, DE 19746585 and DE 1 98 54 096, and modifications thereof that are evident to the person skilled in the art. Suitable micro-mixers may consist of suitable metallic, ceramic or polymeric materials or of silicon.

35 Problematic formulations in the W/O area are emulsions, in particular those having high contents of vegetable triglycerides. Emulsions without

stabilising waxes are frequently distinguished by inadequate long-term viscosity constancy, and O/W lotions are generally more difficult to stabilise than creams. These emulsions can therefore be prepared particularly well using micromixers. It is of particular advantage here than the use of micromixers enables particularly small amounts to be prepared, which can advantageously be prepared in situ, i.e. directly before use.

Microemulsions are thermodynamically stable if, owing to extremely low interfacial energy, they are formed spontaneously, i.e. without the supply of external mechanical energy. The droplet diameters are significantly smaller than in the case of macroemulsions; they are in the range 10-30 nm (nanometers), i.e. below the wavelength of visible light. Microemulsions are therefore colloidally disperse, optically transparent systems. According to POHLER, certain concentration ranges of the oil and water phases and of the emulsifiers and auxiliaries must be observed for the formulation of microemulsions:

Surfactants (usually nonionic surfactants) 15 - 40%

Mineral oil or vegetable oil 5 - 25%

Polyalcohols 0 - 20%

Water 35 - 65%

The use of micromixers for the preparation of microemulsions enables the use of surfactants to be considerably reduced, enabling the toleration for particularly sensitive skin types to be significantly increased. Stable microemulsions can be prepared using as little as less than 10% by weight of surfactants.

The most important requirements of emulsification equipment are usually adequate and in particular variable emulsification power, sufficient shear or impact forces, fitting-out for uniform treatment of the batch, vacuum device, heating and cooling (14). These problems can be solved in a simple manner in accordance with the invention through the use of suitable micromixers, which ensure specific input of energy in each

volume element and in which intensive mixing takes place in the thin channels with exposure to intensive shear forces.

The use of micromixers furthermore enables very small amounts of the desired cosmetic or pharmaceutical formulations to be prepared immediately before use. This has the advantage that the addition of emulsifiers, suspension aids and dispersion aids in the form of surfactants and other additives, such as, for example, stabilisers, can be greatly restricted or their use can be omitted entirely. It is also possible in this way for active ingredients or additives which are incompatible with one another in a formulation over an extended period not to be mixed with one another until directly before use.

Active ingredients which are only stable in a formulation in the form of a derivative can be initially introduced as such in a separate formulation and not added to the remaining mixture until directly before use. This also enables the user to add various additives, as desired, to small amounts of a base mixture at various points in time. This may be of interest both for pharmaceutical and for cosmetic formulations if different active ingredients are to be applied at different points in time.

Different additives can be added to a cosmetic base formulation for the day than for the night. Additives for the day may be, for example, UV filters, while those for the night may be regenerating additives.

For better understanding and for illustration, examples are given below which fall within the scope of protection of the present invention, but are not suitable for restricting the invention to these examples.

Example 1

Hand and nail cream

Raw material	INCI	% W/W
A Paraffin (Art. No. 107162)	(1) Mineral Oil	2.00
Arlamol HD	(2) Isohexadecane	2.00

Preparation:

Notes:

35 pH_{25°C} value: 5.5
Viscosity: 43000 mPa.s (Brookfield RVT, spindle C, 5 rpm, Helipath) at 25°C
0.05% of propyl 4-hydroxybenzoate (Merck KGaA, Art. No. 130173),

0.15% of methyl 4-hydroxybenzoate (Merck KGaA, Art. No. 13 0174),
0.30% of Germall 115 (ISP, Frechen)

Procurement sources:

- (1) Merck KGaA, Darmstadt
- (2) ICI Surfactants, Essen
- (3) Henkel KGaA, Düsseldorf
- (4) Gustav Hees, Stuttgart
- (5) Rhodia, Frankfurt
- (6) Seppic, France
- (7) BASF, Ludwigshafen
- (8) HandR, Holzminden

Example 2

W/O body-care milk (COLD PREPARATION)

5	A. ARLACEL 780	5.0 %
	Paraffin oil, low-viscosity	10.0 %
	Miglyol 812	4.0 %
	ARLAMOL HD	5.0 %
	ARLAMOL E	1.0 %
	Perfume (if desired)	q.s.
10		
15	B. Glycerin	2.5 %
	ATLAS G-2330	1.5 %
	Mg SO ₄	0.5 %
	Demin. water	70.5 %
	Preservative (if desired)	q.s.

Preparation method:

The two phases A and B are each introduced separately into a stock container. After mixing, which can be carried out either by stirring or in small vessels by shaking, the phases are pumped out of the stock containers and passed jointly through a micro-mixer, in which the phases are mixed intensively. The homogeneously mixed milk can be used directly.

Viscosity:

10 000 mPa s (Brookfield LVT Helipath, spindle C, 6 rpm, 1 min.)

Procurement sources:

(1) ICI Surfactants

Example 3

Sun-protection milk (W/S) (water in silicone)

5	A	Eusolex 2292 (Art. No. 5382)	(1)	2.00
		DC 1401	(2)	10.00
		DC 3225 C	(2)	10.00
		Dow Corning 344	(2)	10.00
				q.s.
10	B	Eusolex 232 (Art. No. 5372)	(1)	2.00
		Tris(hydroxymethyl)-	(1)	0.88
		aminomethane (Art. No. 8386)		
		No. 6400)	(1)	2.00
15				Sodium chloride (Art.
			(1)	2.00
				Glycerin (Art.-Nr. 4093)
			(1)	5.00
20				Preservative (if
				desired.)
				q.s.
				Water,
		demineralised		to 100.00

Preparation:

In order to prepare phase B, tris(hydroxymethyl)aminomethane for neutralisation of Eusolex 232 is dissolved in water in a stock vessel, and Eusolex 232 is added. After complete dissolution, the remaining raw materials of phase B are added. The components of phase A are pre-mixed in a second stock vessel.

In order to prepare the sun-protection milk, the two phases are, for mixing, pumped jointly with the aid of a pump through a micromixer connected via thin connecting tubes.

Notes

Viscosity 22,800 mPas (Brookfield RVT, spindle C, 10 rpm) at 25 °C
Samples contain the following as preservatives:
0.05% of propyl 4-hydroxybenzoate (Merck Art. No. 7427)
0.17 % of methyl 4-hydroxybenzoate, sodium salt (Merck Art. No. 6756)

Procurement sources:

- (1) E. Merck, Darmstadt
- (2) Dow Corning, Düsseldorf

Example 4

Transparent microemulsion

Trade name	INCI	% by weight
Eumulgin B2	Ceteareth-20	19.5
Cetiol RE	PEG-7 Glyceryl Cocoate	20.0
Uniphen P-23	Phenoxyethanol + Methyl-/Ethyl-/Propyl-/Butylparaben	0.3
Mineral oil	Mineral Oil	5.0
Glycerin	Glycerin	20.0
Water, demin..	Water	35.2

Preparation:

1. Eumulgin B2, Cetiol HE, Uniphen P-23 and the paraffin oil are introduced into a stock vessel, melted with mixing and heated to about 95°C-105°C.
2. Water and the glycerin are combined and likewise heated to about 95°C-100°C. Increase the amount of water by 3%.
3. The water phase and the fat phase are pumped through a micromixer for intensive mixing. The resultant microemulsion gel stirs for cooling.

Alternatively, it is possible to pass the microemulsion gel through a further, cooled micromixer whose exit channels have a broader cross section, thus preventing blockage of the channels and suppressing the formation of air bubbles in the gel.

At a temperature at which the microemulsion gel is still just pourable, it is transferred into the primary packaging.

Example 5

Sun-protection gel (emulsifier-free)

SPF 3.21 UVA PF 2.5 (sun protection factor, Diffey Method)

5

% by weight

10

A	Eusolex 2292 (Art. No. 105382)	(1)	1.000
	Luvitol EHO	(2)	9.000
	Dow Corning 200 (100 cs)	(3)	2.000
	Antaron V-220	(4)	2.000
	Joboba oil	(5)	5.000
	DL- α -Tocopherol acetate (Art. No. 500952)	(1)	0.500

15

B	Tris(hydroxymethyl)aminomethane (Art. No. 108386)	(1)	0.700
	Water, demineralised		14.300

20

C	Pemulen TR-1	(6)	0.600
	Preservative (if desired)	(1)	q.s.
	Water, demineralised		to 100.000

D	Aloe Vera Gel 1: 10	(7)	1.000
---	---------------------	-----	-------

Preparation:

25

For phase C, homogeneously disperse the Pemulen TR-1 in water, add preservative and pre-swell. Introduce phase B into phase C with homogenisation. Dissolve phase A with heating and add slowly with homogenisation. Add phase D at 35°C and again homogenise.

30

Notes:

Viscosity 67,000 mPas (Brookfield RVT, spindle C, 5 rpm) at 25°C

PH_{25°C} = 6.9

As preservative, 1.0% of phenoxyethanol (Merck Art. No. 807291) can be added.

35

Procurement sources

- 5
- (1) Merck KGaA, Darmstadt

(2) BASF, Ludwigshafen

(3) Dow Corning, Düsseldorf

(4) GAF, Frechen

(5) Henry Lamotte, Bremen

(6) Goodrich, Neuss

(7) Rahn, Maintal

Example 6

In situ W/O/W super-moisturising cream

Composition:

10

15

20

25

30

35

	W/W
A.	
'Brij 721	2.0
Brij 72	3.0
Arlacel P135	0.5
Arlamol E	5.0
Arlamol HD	4.0
Vitamin E acetate	1.0
Laurex CS	1.0
Stearic acid	1.5
Mirasil DM 100	1.0
B	
1.2-Propylene glycol	4.0
Allantoin	0.2
Urea	0.5
Water	74.4
C	
Germaben II	1.0

D. (if desired)

Perfume L94-5770 0.1

Preparation:

1. A and B are warmed to a temperature of 75°C in separate stock containers.
2. Before the emulsion is prepared, C is added to B.
3. The phases A and B/C are mixed intensively by pumping them through a micromixer held at 75°C.
4. The resultant emulsion is collected in a stock vessel.
5. If desired, D is added after cooling to a temperature below 35°C.
6. Further cooling to room temperature is carried out with gentle stirring.

Notes:

Viscosity 43,000 mPa.s (Brookfield LVT T-bar spindle, E, rpm 6, 1 min.)

Example 7

W/O/W face moisturiser
(two-step preparation)

Composition:

Primary emulsion W/O

% W/W

- | | | |
|-----------|--------------|------|
| A. | Arlacel 1M0 | 3.3 |
| | Arlacel 2064 | 3.0 |
| | Arlamol HD | 15.0 |
| | Arlamol M812 | 14.0 |
| B | Water | 63.7 |
| | Germaben II | 1.0 |

- 17 -

Secondary emulsion W/O/W

A. Primary emulsion W/O 50.0

B. 'Arlatone 2121 5.0

Water 44.1

Keltrol 0.4

C. Germaben II 0.5

Preparation:

Primary emulsion W/O

1. B is slowly added to A with vigorous stirring.
2. The resultant emulsion is homogenised for a further 5 minutes.

Secondary emulsion W/O/W

1. The composition indicated under B with the exception of Keltrol is warmed to a temperature of 80°C. Keltrol is dispersed in the initially introduced composition with stirring at constant temperature.

The two separately prepared compositions A and B are mixed in a micromixer as described above.

2. C is added to the emulsion cooled to a temperature below 40°C.

3. The mixture is cooled to room temperature with gentle stirring..

Notes::

Viscosity 16,000 mPa.s (Brookfield LVT, T-) spindle D, rpm 6, min.)

PATENT CLAIMS

1. Process for the preparation of cosmetic or pharmaceutical formulations immediately before use, characterised in that two or more liquid components from separate stock chambers are mixed with one another by passing them through a micromixer.
2. Process for the preparation of cosmetic formulations, characterised in that, characterised in that two or more components in liquid form, if necessary after warming, from separate stock chambers are passed through a micromixer for mixing.
3. Process according to Claims 1 to 2, characterised in that two or more components in liquid form, if necessary after warming, from separate stock chambers are passed through a temperature-controlled micromixer for mixing and subsequently stirred.
4. Process for the preparation of cosmetic formulations in the form of emulsions immediately before use, characterised in that one or more liquid component(s) with one or more natural, synthetic or semi-synthetic oil(s) from separate stock chambers are mixed with one another by passing them through a micromixer.
5. Process for the preparation of cosmetic formulations in the form of emulsions immediately before use, characterised in that a fat phase consisting of one or more natural, synthetic or semi-synthetic oil(s) and one or more fat(s) which is (are) solid at room temperature, is liquefied in a stock chamber by warming, and this liquid fat phase is mixed with one or more liquid component(s) and, if desired, with a further oil phase by passing them through a micromixer.
6. Process according to Claims 1 to 5, characterised in that the components to be mixed are pumped from the stock chambers and fed into a micromixer through connecting thin tubes, each of which terminates in a channel of the micromixer, and forced through the channels of the

micromixer owing to the pressure building up due to the pumping, with intensive mixing and formation of an emulsion.

- 5 7. Process according to Claims 1, 4 to 6, characterised in that the components to be mixed are pumped from the pressurised stock chambers, fed into a micromixer through connecting thin tubes, each of which terminates in a channel of the micromixer, and forced through the channels of the micromixer owing to the pressure which builds up due to the pumping, with intensive mixing and formation of an emulsion.
- 10
- 15 8. Process for the preparation of liposome-containing formulations immediately before use, characterised in that one or more liquid component(s) with a component containing liposome-forming contents from separate stock chambers are mixed with one another by passing them through a micromixer with formation of the desired liposomes.
- 20 9. Process for the preparation of liposome-containing formulations according to Claim 8, characterised in that one or more of the component(s) to be mixed is (are) warmed before preparation of the formulation.
- 25 10. Process according to Claims 8 to 9, characterised in that characterised in that the components to be mixed are pumped from the stock chambers and fed into a micromixer through connecting thin tubes, each of which terminates in a channel of the micromixer, and forced through the channels of the micromixer owing to the pressure which builds up due to the pumping, with intensive mixing and formation of a liposome-containing formulation.
- 30
- 35 11. Process according to Claims 8 to 10, characterised in that the components to be mixed are pumped from pressurised stock chambers and fed into a micromixer through connecting thin tubes, each of which terminates in a channel of the micromixer, and forced through the channels of the micromixer owing to the pressure which builds up due

to the pumping, with intensive mixing and formation of a liposome-containing formulation.

12. Lotion or solution, prepared by a process according to Claims 1 to 11.

13. Emulsion, prepared by a process according to Claims 1 to 11.

14. Gel, prepared by a process according to Claims 1 to 11.

15. Cream, prepared by a process according to Claims 1 to 11.

DECLARATION FOR PATENT APPLICATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

METHOD FOR PRODUCING COSMETIC OR PHARMACEUTICAL FORMULATIONS BY MEANS OF A MICROMIXTURE DIRECTLY BEFORE USE

the specification of which

☐ is attached hereto

☒ was filed on 7 MARCH 2000 as United States Application Number or PCT International Application Number PCT/EP00/01974 and (if applicable) was amended on _____

I hereby authorize our attorneys to insert the serial number assigned to this application.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR §1.56.

I hereby claim foreign priority benefits under 35 U.S.C. §119(a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate, or §365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.

PRIOR FOREIGN/PCT APPLICATION(S) AND ANY PRIORITY CLAIMS UNDER 35 USC §119			
APPLICATION NO.	COUNTRY	DAY/MONTH/YEAR FILED	PRIORITY CLAIMED
199 11 777.2	GERMANY	17 MARCH 1999	YES

I hereby claim the benefit under 35 U.S.C. §119(e) of any United States provisional application(s) listed below.

PROVISIONAL APPLICATION(S) UNDER 35 U.S.C. §119(e)	
APPLICATION NUMBER	FILING DATE

I hereby claim the benefit under 35 U.S.C. §120 of any United States application, or §365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. §112.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR §1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application.

PRIOR U.S./PCT INTERNATIONAL APPLICATION(S) DESIGNATED FOR BENEFIT UNDER 37 U.S.C. §120		
APPLICATION NO.	FILING DATE	STATUS — PATENTED, PENDING, ABANDONED

I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected herewith: I. William Millen (19,544); John L. White (17,746); Anthony J. Zelano (27,969); Alan E.J. Branigan (20,565); John R. Moses (24,983); Harry B. Shubin (32,004); Brion P. Heaney (32,542); Richard J. Traverso (30,595); John A. Sopp (33,103); Richard M. Lebovitz (37,067); John H. Thomas (33,460); Catherine M. Joyce (40,668); Nancy J. Axelrod (44,014); James T. Moore (35,619); James E. Ruland (37,432); Jennifer J. Branigan (40,921) and Robert E. McCarthy (46,044)

Send Correspondence to Customer Number 23599



23599

PATENT TRADEMARK OFFICE

POWER OF ATTORNEY: As a named inventor, I hereby appoint

I. William Millen (Reg. No. 19,544)
 John L. White (Reg. No. 17,746)
 Anthony J. Zelano (Reg. No. 27,969)
 Alan E.J. Branigan (Reg. No. 20,565)
 John R. Moses (Reg. No. 24,983)
 Harry B. Shubin (Reg. No. 32,004)
 Brion P. Heaney (Reg. No. 32,542)
 Richard J. Traverso (Reg. No. 30,595)

John A. Sopp (Reg. No. 33,103)
 Richard M. Lebovitz (Reg. No. 37,067)
 John H. Thomas (Reg. No. 33,460)
 Catherine M. Joyce (Reg. No. 40,668)
 James T. Moore (Reg. No. 35,619)
 James E. Ruland (Reg. No. 37,432)
 Nancy Axelrod (Reg. No. 44,014)
 Jennifer J. Branigan (Reg. No. 40,921)

to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

Send Correspondence to: MILLEN; WHITE; ZELANO & BRANIGAN, P.C.

Arlington Courthouse Plaza I
2200 Clarendon Blvd., Suite 1400
Arlington, VA 22201

Direct Telephone Calls to: (name and telephone number)

Full name of sole or first inventor	22.10.2001
<u>BUENGER, Joachim</u>	Date
Sole or first inventor's	
Residence	
<u>Wilhelm-Leuschner-Strasse 181, D-64823 Gross-Umstadt-Heubach, Germany</u>	DEX
Citizenship	
<u>Germany</u>	
Post Office Address	
<u>c/o Merck KGaA, Frankfurter Str. 250, 64293 Darmstadt, Germany</u>	

Full name of second inventor, if any	22.10.2001
<u>DRILLER, Hans-Juergen</u>	Date
Second inventor's signature	
<u>Hans-Juergen Driller</u>	
Residence	
<u>Santo-Tirso-Ring 71, D-64823 Gross-Umstadt, Germany</u>	DEX
Citizenship	
<u>Germany</u>	
Post Office Address	
<u>c/o Merck KGaA, Frankfurter Str. 250, 64293 Darmstadt, Germany</u>	

3-0

Full name of third inventor, if any	22.10.2001
ZUR LAGE, Jutta	Date
Third inventor's signature	
Residence	
Kapstrasse 11, D-64289 Darmstadt, Germany	DEX
Citizenship	
Germany	
Post Office Address	
c/o Merck KGaA, Frankfurter Str. 250, 64293 Darmstadt, Germany	


4-0

Full name of fourth inventor, if any	22.10.2001
WAGNER, Annette	Date
Fourth inventor's signature	
Residence	
Adolf-Leweke-Strasse 10E, D-60435 Frankfurt, Germany	DEX
Citizenship	
Germany	
Post Office Address	
c/o Merck KGaA, Frankfurter Str. 250, 64293 Darmstadt, Germany	

Full name of fifth inventor, if any
Fifth inventor's signature
Date
Residence
Citizenship
Post Office Address

Full name of sixth inventor, if any
Sixth inventor's signature
Date
Residence
Citizenship
Post Office Address

United States Patent & Trademark Office
Office of Initial Patent Examination -- Scanning Division



Application deficiencies found during scanning:

☒ Page(s) 2, 5 of Specification were not present
for scanning. (Document title)

☒ Page(s) 2 of declaration were not present
for scanning. (Document title)

☐ *Scanned copy is best available.*